Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jdrf
Headquarters: New York, NY, United States of America
Website: http://jdrf.org
Year Founded: 1970
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 15, 2024
Finance
Venture Report: Halda bringing RIPTACs into clinic with crossover round
Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis
BioCentury | Mar 1, 2024
Finance
Public equity report: PIPEs, follow-ons for 11 biotechs add up to $3B+
Viking, Celldex, Janux offerings top list of follow-ons; Denali, Crinetics, Avidity among those raising PIPEs
BioCentury | Feb 2, 2024
Finance
VC roundup: New funds for TCG and Seroba, rounds for Cour and Aqemia
Plus fresh cash for Halia and Neophore, and a new spinout from venture-backed Cumulus Oncology
BioCentury | Dec 15, 2023
Finance
Sofinnova Partners spreading Biovelocita accelerator beyond Italy in new strategy
After eight years advancing academic projects in country with relative dearth of management, veteran VC now seeking ‘pan-European’ goals
BioCentury | Oct 2, 2023
Regulation
Oct. 2 Quick Takes: Takeda withdrawing Exkivity after confirmatory miss
Plus: Novartis’ iptacopan shows benefit in IgA nephropathy and updates from Mirum, Lexeo, Rocket, Lilly, Syndax, SAB, Amicus and Pneumagen
BioCentury | Jun 21, 2023
Management Tracks
Jonathan Mow named CEO at Veralox
Plus: Ottesen becomes CMO at Adcendo, and updates from Splice Bio, Shape, C4 and more
BioCentury | May 10, 2023
Deals
May 10 Quick Takes: Bicycle in third radiopharma deal of year
Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more
BioCentury | Mar 13, 2023
Deals
Sanofi takeout of Provention puts disease interception to the commercial test
Sanofi acquiring Provention for $2.9B to take over Type I diabetes launch, advance disease interception pipeline
BioCentury | Nov 16, 2022
Deals
Kriya rolls up Redpin, adds neurology to its gene therapy scope
In second M&A deal this year, Patient Square-backed Kriya adds epilepsy, trigeminal neuralgia programs along with platform in ‘nine-digit’ acquisition
BioCentury | Sep 7, 2022
Management Tracks
Harpoon’s McMahon becomes CEO at Storm
Plus new CFO, CSO at Voyager and updates from Sonoma, Garuda, Alloy, Homology and more
Items per page:
1 - 10 of 129